Sales of Tamiflu dropped precipitously thanks to a weak flu season, helping to push first-quarter earnings down 24 percent. Lower-than-expected results sparked a selloff, but analysts quickly dismissed concern that the fundamentals were awry. Oppenheimer’s Bret Holley and Baird’s Thomas J. Russo kept their “outperform’’ ratings, expecting sales to recover rapidly.
© Copyright 2011 Globe Newspaper Company.
